The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Extended rhodamine compounds exhibiting favorable fluorescence characteristics having the structure ##STR00001##
are disclosed. In addition, novel intermediates for synthesis of these dyes are disclosed, such intermediates having the structure ##STR00002## In addition, methods of making and using the dyes as fluorescent labels are disclosed.

Extended rhodamine compounds exhibiting favorable fluorescence characteristics having the structure ##STR00001##
are disclosed. In addition, novel intermediates for synthesis of these dyes are disclosed, such intermediates having the structure ##STR00002## In addition, methods of making and using the dyes as fluorescent labels are disclosed.

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

Described is a compound of Formula II1, a method of manufacturing thereof as well as uses thereof.

##STR00001##

Described is a compound of Formula II1, a method of manufacturing thereof as well as uses thereof.

##STR00001##

There is disclosed a compound of Formula (III), a method for manufacturing thereof as well as uses thereof.

##STR00001##

There is disclosed a compound of Formula (III), a method for manufacturing thereof as well as uses thereof.

##STR00001##